<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783300</url>
  </required_header>
  <id_info>
    <org_study_id>204653</org_study_id>
    <secondary_id>2016-000278-39</secondary_id>
    <nct_id>NCT02783300</nct_id>
  </id_info>
  <brief_title>An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma</brief_title>
  <acronym>Meteor 1</acronym>
  <official_title>A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first time in human (FTIH) open-label, dose escalation study will assess the safety,&#xD;
      pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595&#xD;
      in participants with advanced or recurrent solid tumors, as well as clinical activity in&#xD;
      participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2016</start_date>
  <completion_date type="Anticipated">April 29, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a three-part study where Part 1 is dose escalation, including assessment of Food Effect and Relative Bioavailability, Part 2 is disease specific expansion cohorts to better characterize the clinical activity and safety profile of GSK3326595 and Part 3 is dose determination of GSK3326595 in combination with pembrolizumab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 3: Number of participants with any adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs, dose interruptions and reductions</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>All AEs, SAEs and dose modifications will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>An event is considered to be a DLT if the event occurs within the first 21 days of treatment and meets the dose-limiting toxicity criteria, unless it can be clearly established that the event is unrelated to treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 3: Number of participants with clinically significant changes in laboratory parameters, vital signs, physical examination and organ-specific parameters.</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood and urine samples will be collected for analysis of lab parameters. Vital signs, physical examinations and organ-specific parameters will be collected at specified time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Participants with solid tumors (non-GBM): Overall response rate (ORR) based on Evaluation Criteria In Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. ACC tablet cohort will score ORR by independent central review, all other non-GBM solid tumor cohorts will score ORR by investigator assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Participants with NHL: ORR based on Lugano criteria</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants achieving CR or PR based on Lugano criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: GBM cohort: Six-month progression free survival (PFS) rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>PFS is defined as the percentage of participants free from radiographic progression per Response Assessment in Neuro-Oncology (RANO) criteria, or death due to any cause, for six months after starting GSK3326595.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Change from Baseline in symmetrical arginine dimethylation (SDMA) as a PD measure</measure>
    <time_frame>Baseline and up to approximately 2 years</time_frame>
    <description>Evaluation of change from baseline in SDMA, a PD biomarker of PRMT5 inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: Maximum observed plasma concentration (Cmax) of GSK3326595</measure>
    <time_frame>Baseline and up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the Cmax of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: Area under the plasma concentration-time curve (AUC) extrapolated from time zero to infinity (AUC[0-inf]) of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the AUC (0-inf) of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the AUC (0-t) of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: AUC over the dosing interval tau (AUC[0-tau]) of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the AUC (0-tau) of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: Terminal phase half-life (t1/2) of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the half-life of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: Oral clearance (CL/F) of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the CL/F of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: Accumulation ratio (AR) of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the AR of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 3: Time invariance (TI) of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected at given time points to determine the TI of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2 (Participants with ACC only) ORR based on RECIST 1.1 criteria</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) based on RANO working group criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: ORR based on immune-based RECIST (iRECIST) criteria</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants achieving confirmed CR or confirmed PR based on immune-based RECIST (iRECIST) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PFS</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from first dose until radiographic progression per standard criteria or death due to any cause, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: ORR in participants with GBM based on Response Assessment Neuro-Oncology (RANO) Working group criteria</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) based on RANO working group criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: (Participants in ACC tablet cohort): Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>DOR is defined as the time from first evidence of response (CR or PR per RECIST 1.1) to earlier date of disease progression or death due to any cause, as determined by ICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: (Participants in ACC tablet cohort): Overall survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>OS is defined as the time from first dose until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of participants with any AEs, SAEs, withdrawal due to AEs, dose reductions or delays</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>All AEs, SAEs and dose modifications will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of participants with clinically significant changes in laboratory parameters, vital signs, physical examination and organ-specific parameters</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood and urine samples will be collected for analysis of lab parameters. Vital signs, physical examinations and organ-specific parameters will be collected at specified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: ORR relative to p53 mutational status in participants with NHL</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>P53 mutational status is collected for participants with NHL to determine the relationship between p53 status and ORR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected to determine AUC of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of GSK3326595</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Blood samples will be collected to determine Cmax of GSK3326595.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of GSK3326595 until the maximum tolerated dose level is reached. The recommended phase 2 dose (RP2D) will be determined. Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of GSK3326595, and will be dosed with tablet and capsule to compare two formulations of GSK3326595 (capsule versus tablet).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Disease-Specific Expansion cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with triple-negative breast cancer (TNBC), metastatic transitional cell carcinoma of the urinary system (mTCC), Grade IV anaplastic astrocytoma (glioblastoma multiforme [GBM]), non-Hodgkin's lymphoma (NHL), adenoid cystic carcinoma (ACC), hormone receptor-positive adenocarcinoma of the breast (ER+BC), human papillomavirus (HPV)-positive solid tumors of any histology, and p53-wild type non-small cell lung cancer (NSCLC) will be administered GSK3326595 at the recommended phase 2 dose (RP2D) as determined in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: GSK3326595 in combination with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with selected solid tumors will be administered GSK3326595 in combination with pembrolizumab as part of this dose determination study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3326595</intervention_name>
    <description>GSK3326595 will be administered with and without food, in tablet and capsule formulation.</description>
    <arm_group_label>Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet</arm_group_label>
    <arm_group_label>Part 2: Disease-Specific Expansion cohort</arm_group_label>
    <arm_group_label>Part 3: GSK3326595 in combination with pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered.</description>
    <arm_group_label>Part 3: GSK3326595 in combination with pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Males and females greater than or equal to (&gt;=)18 years of age (at the time consent is&#xD;
             obtained)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 or 2&#xD;
&#xD;
          -  Diagnosis of non-resectable or metastatic solid malignancy (as defined in the&#xD;
             protocol) or NHL&#xD;
&#xD;
          -  Presence of evaluable disease&#xD;
&#xD;
          -  Adequate organ function (as defined in the protocol)&#xD;
&#xD;
          -  Reproductive criteria (as defined in the protocol).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignancy attributed to prior solid organ transplant&#xD;
&#xD;
          -  Leptomeningeal disease, spinal cord compression, or brain metastases that require&#xD;
             immediate central nervous system (CNS)-specific treatment in the opinion of the&#xD;
             Investigator (for example [e.g.], for symptomatic disease)&#xD;
&#xD;
          -  History of a second malignancy, excluding non-melanoma skin cell cancer within the&#xD;
             last three years&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic diseases, or serious and/or pre-existing&#xD;
             medical or other condition that could interfere with participant's safety, obtaining&#xD;
             informed consent or compliance to the study procedures, in the opinion of the&#xD;
             Investigator&#xD;
&#xD;
          -  Any clinically significant gastrointestinal (GI) abnormalities that may alter&#xD;
             absorption such as malabsorption syndrome or major resection of the stomach and/or&#xD;
             bowels.&#xD;
&#xD;
          -  Select cardiac abnormalities (as defined in the protocol)&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or Medical&#xD;
             Monitor, contraindicates their participation.&#xD;
&#xD;
          -  History of optic nerve neuropathy or neuritis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Falchook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Izidore S Lossos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mrinal M. Gounder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mrinal M. Gounder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mrinal M. Gounder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Meredith Ann McKean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Drew W Rasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Quincy Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Hilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lillian Siu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antoine Italiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Cassier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frans L. Opdam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joost S.P. Vermaat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maja J.A. de Jonge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK3326595</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Non-Hodgkin's lymphoma (NHL)</keyword>
  <keyword>Urinary tract cancer</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Adenoid cystic carcinoma (ACC)</keyword>
  <keyword>Non small-cell lung cancer (NSCLC)</keyword>
  <keyword>Squamous cell carcinoma of the head and neck (HNSCC)</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>GSK-3326595</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

